Symbols

BCPC

Balchem·NASDAQ

--(--)

BCPC fundamentals

BCPC Q4 2025 Earnings

Balchem (BCPC) released its earnings on Feb 20, 2026: revenue was 263.62M (YoY +9.84%), beat estimates; EPS was 1.21 (YoY +17.48%), beat estimates.

Revenue / YoY

263.62M

+9.84%

EPS / YoY

1.21

+17.48%

Report date

Feb 20, 2026

BCPC Earnings Call Summary for Q4,2025

Record Year Achieved: Balchem surpassed $1 billion in annual sales for the first time, with 8.8% YoY growth and 9.8% EBITDA expansion.
Segment Strength: Human Nutrition & Health led with 12.7% sales growth, driven by better-for-you food trends and international expansion.
Clinical Trial Momentum: A Phase 2 study on choline and Alzheimer's disease is expected in 2026, with potential to unlock new health claims.
Sustainability Success: Exceeded 2030 GHG reduction target, cutting emissions by 31% since 2020.
Financial Health: 0.3x net debt leverage and $75 million cash on hand highlight strong balance sheet.

Earnings

EPS

Revenue

Revenue & Expenses

BCPC has released its 2025 Q4 earnings report, with revenue of 263.62M, reflecting a YoY change of 9.84%, and net profit of 39.23M, showing a YoY change of 16.80%. The Sankey diagram below clearly presents BCPC's revenue sources and cost distribution.

Key Indicators

Balchem (BCPC) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Balchem (BCPC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Balchem (BCPC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Balchem (BCPC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown